Diagnosing hypertension in children

March 13, 2020

HighlightWashington, DC -- Results from a new study provide insights on evaluating high blood pressure in children. The findings appear in an upcoming issue of CJASN.

Diagnostic workup for hypertension in children may include wearing a device that monitors blood pressure over 24 hours. Blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--is used in addition to average blood pressure as part of the criteria for diagnosing hypertension in children. Use of blood pressure load in everyday practice may lead to confusion in scenarios where a child has elevated blood pressure load but normal average blood pressure, however, and it's unclear how a high blood pressure load (with normal average blood pressure) affects long-term health.

To provide insight, Jason Lee, MD (University of California, San Francisco) and his colleagues studied 533 children with chronic kidney disease who underwent 24-hour blood pressure monitoring, along with tests related to kidney and heart health over several years. Based on 24-hour blood pressure data, the team grouped children as having normal blood pressure, high blood pressure load but without high average blood pressure, and high average blood pressure.

One-quarter of the children had high blood pressure load. Having high blood pressure load by itself was not associated with higher risks of developing kidney failure or a condition called left ventricular hypertrophy (thickening of the heart), which can develop in response high blood pressure.

"Our data suggest that the proportion of readings on a 24-hour blood pressure test that are high may not provide additional insight beyond the average blood pressure values surrounding a child's risk for developing cardiac disease or worsening kidney disease," said Dr. Lee. "However, having a high average blood pressure on a 24-hour blood pressure test does strongly predict a child's cardiac and kidney disease risk."
-end-
Study co-authors include Charles E. McCulloch, PhD, Joseph T. Flynn, MD, MS, Joshua Samuels, MD, MPH, Bradley A. Warady, MD, Susan L. Furth, MD, PhD, Divya Seth, BA, Barbara A. Grimes, PhD, Mark M. Mitsnefes, MD, MS, and Elaine Ku, MD, MAS.

Disclosures: Dr. Flynn reports grants from NIDDK, during the conduct of the study; personal fees from Silvergate Pharmaceuticals, personal fees from Ultragenyx, personal fees from Vertex Pharmaceuticals, personal fees from Up To Date, outside the current work. Dr. Ku reports consulting fees from Tricida and grants from NIDDK and NHLBI. Dr. Mitsnefes reports grants from NIDDK.

The article, entitled "Prognostic Value of Ambulatory Blood Pressure Load in Pediatric Chronic Kidney Disease," appears online at https://cjasn.asnjournals.org/content/early/2020/03/10/CJN.10130819, doi: 10.2215/CJN.10130819.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, the American Society of Nephrology (ASN) has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit http://www.asn-online.org.

American Society of Nephrology

Related Hypertension Articles from Brightsurf:

Overactive enzyme causes hereditary hypertension
After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure.

Diagnosing hypertension in children
Study results call into question the utility of testing blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--for diagnosing hypertension in children.

When the best treatment for hypertension is to wait
A new study concluded that a physician's decision not to intensify hypertension treatment is often a contextually appropriate choice.

Treatment of hypertension induced albuminuria
Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria.

Diagnosing and treating resistant hypertension
Resistant blood pressure affects 12 percent to 15 percent of people currently being treated for high blood pressure.

Dementia can be caused by hypertension
A new study in Cardiovascular Research indicates that patients with high blood pressure are at a higher risk of developing dementia.

Hormone imbalance causes treatment-resistant hypertension
British researchers have discovered a hormone imbalance that explains why it is very difficult to control blood pressure in around 10 per cent of hypertension patients.

Breastfeeding reduces hypertension risk
A study published in the American Journal of Hypertension indicates that women who breastfeed more children, and for longer periods of time, are less likely to suffer from hypertension after they reach menopause.

Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

Targeting mitochondria in pulmonary hypertension
Investigators at the University of Alberta and the Imperial College of Medicine have shown that the generic drug, Dichloroacetate (DCA), can decrease the blood pressure in the lungs of pulmonary arterial hypertension patients and improve their ability to walk, without significant side effects at the doses tested.

Read More: Hypertension News and Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.